Cannabinoids for the treatment of dementia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Markovic, Domagoj ^a   Bošnjak, Dina ^b   Brkovic, Tonci ^a   Jeric, Milka ^c   Rubic, Zana ^a   Vuica Vukasović, Ana ^a   Puljak, Livia ^d  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b Psychiatric Hospital Vrap e   (Croatia)

^c GENERAL HOSPITAL ZADAR   (Croatia)

^d UNIVERSITY OF SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABIS; DRONABINOL; ENDOCANNABINOID; NABILONE; TETRAHYDROCANNABINOLIC ACID;

ACTIMETRY; ADVERSE EVENT; AGGRESSION; AGITATION; ANOREXIA; APPETITE; ARTICLE; BODY WEIGHT; CAREGIVER; CAREGIVER BURDEN; CIRCADIAN RHYTHM; CLINICAL PROTOCOL; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXECUTIVE FUNCTION; FUNCTIONAL BEHAVIOR; FUNCTIONAL STATUS; HUMAN; MEMORY; MOOD; NEUROPSYCHIATRIC INVENTORY; NIGHT SLEEP; OUTCOME ASSESSMENT; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESSNESS; SLEEP PATTERN; SLEEP QUALITY; SLEEP WAKING CYCLE; SYSTEMATIC REVIEW; WAKEFULNESS; WANDERING BEHAVIOR;

EID: 85030546405     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012820     Document Type: Article

References (80)

1. Alzheimer's Disease International (ADI). World Alzheimer Report 2016. www.alz.co.uk/research/WorldAlzheimerReport2016.pdf (accessed 16 May 2017).
2. Ahmad R, Goffin K, Van den Stock J, De Winter FL, Cleeren E, Bormans G, et al. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. European Neuropsychopharmacology 2014;24(2):242-50.
3. Ahmed A, van der Marck MA, van den Elsen G, Olde Rikkert M. Cannabinoids in late-onset Alzheimer's disease. Clinical Pharmacology and Therapeutics 2015;97(6):597-606.
4. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. Fifth. Arlington, VA: American Psychiatric Publishing, 2013.
5. Aso E, Palomer E, Juves S, Maldonado R, Munoz FJ, Ferrer I. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. Journal of Alzheimer's disease 2012;30(2):439-59.
6. Aso E, Juves S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. Journal of Alzheimer's Disease 2013;35(4):847-58.
7. Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Frontiers in Pharmacology 2014;5:37.
8. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurology 2003;2:291-8.
9. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003476.pub2]
10. Banwell E, Pavisian B, Lee L, Feinstein A. Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis. Multiple Sclerosis and Related Disorders 2016;10:123-6.
11. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. International Journal of Geriatric Psychiatry 2002;17(5):403-8.
12. Brane G, Gottfries CG, Winblad B. The Gottfries-Brane-Steen scale: validity, reliability and application in anti-dementia drug trials. Dementia and Geriatric Cognitive Disorders 2001;12(1):1-14.
13. Brusco A, Tagliaferro PA, Saez T, Onaivi ES. Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Annals of the New York Academy of Sciences 2008;1139:450-7.
14. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine 2009;11:E3.
15. Campbell VA, Gowran A. Alzheimer's disease; taking the edge off with cannabinoids?. British Journal of Pharmacology 2007;152:655-62.
16. Chen X, Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience 2011;178:159-68.
17. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. Journal of Gerontology 1989;44(3):M77-84.
18. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. The BMJ 1997;315(7109):629-34.
20. Ehrhart J, Obergon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of CB2 suppresses microglial activation. Journal of Neuroinflammation 2005;2:29.
21. Thomson Reuters. EndNote. Version EndNote X5. Thomson Reuters, 2011.
22. Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular Pharmaceutics 2006;3:773-7.
23. Centre for Drug Evaluation and Research. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioural disturbances FDA April 2005.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189-98.
25. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11(Suppl 2):S33-9.
26. Gazibara T, Prpic M, Maric G, Pekmezovic T, Kisic-Tepavcevic D. Medical cannabis in Serbia: The survey of knowledge and attitudes in an urban adult population. Journal of Psychoactive Drugs 2017;49(3):217-24.
27. Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neuroscience & Therapeutics 2011;17(6):637-44.
28. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opinion on Investigational Drugs 2002;11:1365-74.
29. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400.
30. Harvey BS, Ohlsson KS, Maag JL, Musgrave IF, Smid SD. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. Neurotoxicology 2012;33(1):138-46.
31. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
32. Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Cannabinoids. Journal of Pain and Symptom Management 2013;46(1):142-9.
33. Howlett AC, Barth F, Bonner T, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology XXVII.Classification of cannabinoid receptors. Pharmacological Reviews 2002;54:161-202.
34. Iversen LL. The Science of Marijuana. Oxford: Oxford University Press, 2000.
35. Janefjord E, Maag JL, Harvey BS, Smid SD. Cannabinoid effects on beta amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cellular and Molecular Neurobiology 2014;34(1):31-42.
36. Jelicic Kadic A, Vucic K, Dosenovic S, Sapunar D, Puljak L. Extracting data from figures with software was faster, with higher interrater reliability than manual extraction. Journal of Clinical Epidemiology 2016;74:119-23.
37. Kaur R, Ambwani SR, Singh S. Endocannabinoid system: A multi-facet therapeutic target. Current Clinical Pharmacology 2016;11(2):110-7.
38. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007204.pub2]
39. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 62;10:e1-34.
40. Liu CS, Chau SA, Ruthirakuhan M, Lanctot KL, Herrmann N. Cannabinoids for the treatment of agitation and aggression in Alzheimer's disease. CNS drugs 2015;29(8):615-23.
41. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biological Psychiatry 2016;79(7):516-25.
42. Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. Trends in Biochemical Sciences 2010;35(11):601-8.
43. Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation 2012;9:8.
44. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
45. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dementia 2011;7(3):263-9.
46. Medicines and Healthcare Products Regulatory Agency (MHRA). New advice issued on risperidone and olanzapine MHRA March 2004.
47. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 2011;134(Pt 4):1041-60.
48. O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores. Archives of Neurology 2008;65(8):1091-5.
49. Onaivi ES. Neuropsychological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006;54:231-46.
50. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Annals of the New York Academy of Sciences 2008;1139:434-49.
51. Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Santamato A, Lozupone M, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Expert Opinion on Pharmacotherapy 2015;16(17):2581-8.
52. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal 2005;7(3):e625-54.
53. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacological Reviews 2010;62(4):588-631.
54. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. Journal of the American Medical Society 1982;248:333-5.
55. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience 2005;25(8):1904-13.
56. Rathbone J, Carter M, Hoffmann T, Glasziou P. Better duplicate detection for systematic reviewers: evaluation of Systematic Review Assistant-Deduplication Module. Systematic Reviews 2015;4:6.
57. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
58. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular Dementia - Diagnostic-Criteria for Research Studies - Report of the Ninds-Airen International Workshop. Neurology 1993;43(2):250-60.
59. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;141(11):1356-64.
60. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease cooperative study - Clinical global impression of change. Alzheimer Disease and Associated Disorders 1997;11:S22-S32.
61. Schneider LS, Dagerman KS, Insel P. Risk of death withatypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
62. Schneider LS, Dagerman KS, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized placebo-controlled trials. American Journal of Geriatric Psychiatry 2006;14:191-210.
63. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH (AUTHORS) on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane. Available from www.cochrane-handbook.org.
64. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metabolism 2013;17(4):475-90.
65. Solas M, Francis PT, Franco R, Ramirez MJ. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging 2013;34(3):805-8.
66. Standfield LB, Comans T, Scuffham P. A simulation of dementia epidemiology and resource use in Australia. Australian and New Zealand Journal of Public Health 2017 Jul 27 [Epub ahead of print]. [DOI: 10.1111/1753-6405.12700]
67. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 1990;147:1049-51.
68. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handbook of Experimental Pharmacology 2005;168:327-65.
69. Tschanz JT, Norton MC, Zandi PP, Lyketsos CG. The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset. International Review of Psychiatry 2013;25(6):673-85.
70. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2017. Market analysis of plant-based drugs. Opiates, cocaine, cannabis. https://www.unodc.org/wdr2017/field/Booklet_3_Plantbased_drugs.pdf (accessed 10 July 2017).
71. van den Elsen GA, Ahmed AI, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology 2015;84(23):2338-46.
72. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-332.
73. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. Journal of Neuroscience 2009;29(14):4564-70.
74. Vucic K, Jelicic Kadic A, Puljak L. Survey of Cochrane protocols found methods for data extraction from figures not mentioned or unclear. Journal of Clinical Epidemiology 2015;68(10):1161-4.
75. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006;185(4):524-8.
76. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015;313(24):2456-73.
77. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, 10th revision. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization, 2010.
78. World Health Organization (WHO). Alzheimer Disease and Other Dementias. www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf (accessed 9 May 2017).
79. Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. American Journal of Geriatric Psychiatry 2014;22(4):415-9.
80. Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiology of Aging 2013;34(3):791-804.